GL and ADT elaborated the search strategy
Outcome measures included glycemic control, weight loss, changes in blood pressure, lipid profile, and common adverse events
This article breaks down every piece of safety data available, the known risks, what happens when you stop, and how to build a protocol that works for the long haul
The TRIUMPH-4 trial showed that retatrutide at 12mg reduced: Systolic blood pressure: 14.0 mmHg reduction Non-HDL cholesterol: clinically meaningful improvement High-sensitivity C-reactive protein: significant reduction (a marker of systemic inflammation) Triglycerides: substantial decrease Tirzepatide produces similar cardiovascular improvements, with well-documented reductions in blood pressure, triglycerides, and inflammatory markers across the SURMOUNT and SURPASS programs
Enjoy consistent check-ins and expert advice as needed